UK Insists No Brexit Impact On Clinical Trial Rates
Top Official Moves To Quash Rumors About UK Performance On Global Stage
Executive Summary
The UK insists there have been no major changes to the clinical trial environment since the country voted to leave the EU more than three years ago. It says the country continues to be an attractive location for clinical research.
You may also be interested in...
UK Clinical Trial Numbers Still ‘Buoyant’ After Brexit
In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.
EU Addresses Complex Clinical Trial Designs In New Guideline
The advent of precision medicine has prompted sponsors to experiment with complex clinical trial designs, which can involve increased operational complexity. A new EU-wide guidance has been issued on the subject to pave the way for a harmonized approach.
UK Smooths Clinical Trial Pathway To Reassure Companies With Brexit Jitters
The UK is revising its clinical trial processes to align them with the new EU Clinical Trials Regulation so that companies can seek authorization just as easily in the UK as in other EU member states, irrespective of the situation after Brexit.